BBNXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Beta Bionics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026

$16.84+0.49 (+3.00%)

Close on Oct 19, 2026

Market cap: $750.14M
P/E (TTM): –
Dividend yield: –

Beta Bionics, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Cash & Equivalents	32	31	27	28
Short-Term Investments	188	73	70	–
Cash & Short-Term Investments	219	104	97	28
Receivables	17	12	4.45	–
Inventory	22	13	1.25	–
Prepaid Expenses & Other	9.84	4.03	1.18	–
Other Current Assets	–	0.82	0.28	–
Total Current Assets	268	133	104	–
Property, Plant & Equipment	8.60	4.78	2.48	–
Gross Property, Plant & Equipment	14	10	6.90	–
Accumulated Depreciation	-5.76	-5.25	-4.42	–
Long-Term Investments	45	–	–	–
Operating Lease Right-of-Use Assets	6.63	6.65	3.72	–
Other Long-Term Assets	0.18	0.15	0.12	–
Total Assets	329	150	110	–
Accounts Payable	5.00	2.85	1.17	–
Current Portion of Leases	1.94	1.53	1.22	–
Deferred Revenue (Current)	1.56	0.94	0.09	–
Total Current Liabilities	31	21	11	–
Long-Term Leases	5.37	5.73	3.00	–
Operating Lease Liabilities	7.30	7.26	4.22	–
Other Long-Term Liabilities	1.55	–	–	–
Total Liabilities	41	74	51	–
Common Stock	0.00	0.00	–	–
Additional Paid-In Capital	657	51	26	–
Retained Earnings	-370	-297	-230	–
Comprehensive Income & Other	0.40	0.07	0.14	–
Shareholders' Equity	288	-245	-203	-170
Total Equity	288	-245	-203	-170
Total Liabilities & Equity	329	150	110	–
Shares Outstanding(shares)	44	6.67	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 58.3%
Operating margin: -69.8%
Net margin: -61.3%
Return on equity, FY2025: -346.5%

Financial strength

Current ratio: 8.88
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 170.3%

Valuation

P/E ratio: –
Price to sales: 6.30
Price to book: 2.93
Dividend yield: –